Vertex commits over £300M to new Oxford research facility
- Vertex said it will invest more than £300 million in a new R&D facility in Oxford, England.
- The pledge was announced alongside the UK Autumn Budget, as part of a wider set of British biopharma investment commitments.
- Press coverage describes a roughly 155,000 sq ft site at Harwell Campus, with the government contributing an undisclosed grant.
💡 Points Based on public reports
£300M-plus is a serious commitment for a company whose cash engine is still cystic fibrosis, and it reads as a bet on research capacity beyond its US hubs as it pushes into pain, kidney and other new areas. The undisclosed government grant is the tell: the UK is now paying to win R&D sites, not just manufacturing.
UK lands £500M in biopharma pledges; Teva to shutter New Jersey site ↗